Semaglutide
Also known as: Ozempic · Wegovy · Rybelsus · GLP-1 RA
Semaglutide is a once-weekly GLP-1 receptor agonist used for type 2 diabetes management and chronic weight management. Provider-reviewed dosing — including microdose strategies — pairs the medication with lean-mass preservation and biomarker recalibration.
Activates GLP-1 receptors in the pancreas, brain, and GI tract to enhance glucose-dependent insulin secretion, slow gastric emptying, and reduce appetite signaling.
What you need to know
Semaglutide is the first widely available once-weekly GLP-1 receptor agonist with substantial body-weight and metabolic effects. The medication amplifies satiety signaling, slows gastric emptying, and improves glucose-dependent insulin secretion. Provider-reviewed pathways address the two most common pitfalls of unmanaged use: lean-mass loss (countered with resistance training and adequate protein) and rebound after discontinuation (countered with structured maintenance and biomarker recalibration). Microdose strategies are used to reduce GI side effects and improve adherence in select candidates.
How this entity relates
Every entity in the oMeds knowledge graph cross-links to the conditions, biomarkers, medications, and educational surfaces it touches.
Monitoring biomarkers
Bring this entity into your optimization pathway
Every condition, symptom, biomarker, and medication on oMeds is reviewed by a licensed provider and recalibrated against the standardized biomarker panel.